Regentatlantic Capital Lowered By $1.10 Million Its Gilead Sciences (GILD) Stake; Supportcom Has 0 Sentiment





August 27, 2017 – By Winifred Garcia







Support.com, Inc. is a provider of cloud software and services for technology support. The company has market cap of $46.02 million. The Firm offers outsourced support services for service providers, retailers, Internet of Things solution providers and technology companies. It currently has negative earnings. It offers technology support services programs for both the consumer and small business markets, and includes computer and mobile device set-up, security and support, virus and malware removal, wireless network set-up, and home security and automation system support.

Regentatlantic Capital Llc decreased Gilead Sciences Inc (GILD) stake by 26.66% reported in 2016Q4 SEC filing. Regentatlantic Capital Llc sold 15,531 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The Regentatlantic Capital Llc holds 42,734 shares with $3.06 million value, down from 58,265 last quarter. Gilead Sciences Inc now has $96.36 billion valuation. The stock decreased 0.31% or $0.23 on August 25, reaching $73.79. About 3.73M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since August 27, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

The stock increased 2.07% or $0.05 on August 25, reaching $2.46. About 18,379 shares traded. Support.com, Inc. (SPRT) has risen 2.28% since August 27, 2016 and is uptrending. It has underperformed by 14.42% the S&P500.

Cornerstone Capital Inc. holds 0.05% of its portfolio in Support.com, Inc. for 290,000 shares. Awm Investment Company Inc. owns 202,663 shares or 0.03% of their US portfolio. Moreover, Ingalls & Snyder Llc has 0.01% invested in the company for 139,039 shares. The New York-based Bank Of New York Mellon Corp has invested 0% in the stock. Blackrock Advisors Llc, a Delaware-based fund reported 48,125 shares.

READ ---  Jerry Jones’ HOF journey: The love of football and love of family

Investors sentiment increased to 0.91 in Q4 2016. Its up 0.21, from 0.7 in 2016Q3. It improved, as 106 investors sold GILD shares while 656 reduced holdings. 111 funds opened positions while 421 raised stakes. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. Dana Advisors accumulated 58,698 shares or 0.2% of the stock. Rockefeller Svcs reported 0.02% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Girard Prtnrs Ltd reported 30,722 shares or 0.64% of all its holdings. St Johns Investment Com Limited Liability Company has invested 0.21% in Gilead Sciences, Inc. (NASDAQ:GILD). The New York-based Hollow Brook Wealth Llc has invested 8.37% in Gilead Sciences, Inc. (NASDAQ:GILD). Nine Chapters Management Limited Liability Company invested in 15,200 shares. Massachusetts-based Seaward Management Ltd Partnership has invested 0.98% in Gilead Sciences, Inc. (NASDAQ:GILD). Quantres Asset Mngmt reported 0.23% in Gilead Sciences, Inc. (NASDAQ:GILD). Nippon Life Ins has invested 0.08% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Glovista Investments Limited Liability Corporation reported 8,335 shares. Shelter Mutual owns 58,100 shares or 1.28% of their US portfolio. Ray Gerald L & Associates owns 67,580 shares. 50,220 are owned by Amer Cap Management Inc. Cullinan Assocs invested 0.27% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). National Asset Mgmt Inc has 28,336 shares for 0.41% of their portfolio.

Regentatlantic Capital Llc increased Royal Dutch Shell Plc stake by 5,790 shares to 18,471 valued at $1.00 million in 2016Q4. It also upped United Therapeutics Corp Del (NASDAQ:UTHR) stake by 2,785 shares and now owns 15,533 shares. Leidos Hldgs Inc (NYSE:LDOS) was raised too.

READ ---  Anthem Partners With CVS Health To Launch New PBM - Forbes

Since March 1, 2017, it had 0 insider purchases, and 8 selling transactions for $21.55 million activity. 73,333 shares were sold by MARTIN JOHN C, worth $4.78 million on Thursday, June 1. 5,000 shares were sold by Alton Gregg H, worth $325,114 on Thursday, June 1. Shares for $668,667 were sold by Cogan John Francis on Tuesday, May 9.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 80 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Neutral” rating by Atlantic Securities on Friday, December 18. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, October 28 by Maxim Group. On Wednesday, February 3 the stock rating was initiated by Standpoint Research with “Buy”. Maxim Group downgraded the shares of GILD in report on Friday, April 29 to “Hold” rating. On Monday, June 12 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by Credit Suisse with “Outperform” on Wednesday, March 23. The rating was maintained by Credit Suisse with “Outperform” on Wednesday, September 14. The rating was downgraded by Leerink Swann to “Mkt Perform” on Tuesday, September 27. The company was maintained on Monday, July 24 by J.P. Morgan. The firm has “Hold” rating given on Wednesday, September 9 by Jefferies.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.

READ ---  The big question in France’s parliamentary elections: Why did so few people vote?

Source